The historical rank and industry rank for WAVE Life Sciences's Days Payable or its related term are showing as below:
FRA:1U5's Days Payable is not ranked *
in the Biotechnology industry.
Industry Median: 113.1 * Ranked among companies with meaningful Days Payable only.
WAVE Life Sciences's Days Payable
stayed the same
from Mar. 2025 (0.00) to Mar. 2026 (0.00).
stayed the same
WAVE Life Sciences Days Payable Related Terms
WAVE Life Sciences Days Payable Historical Data
* Premium members only.
The historical data trend for WAVE Life Sciences's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:1U5 vs CGEM, LXRX, XNCR: Days Payable Comparison
For the Biotechnology subindustry, WAVE Life Sciences's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
WAVE Life Sciences Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, WAVE Life Sciences's Days Payable distribution charts can be found below:
* The bar in red indicates where WAVE Life Sciences's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
WAVE Life Sciences's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WAVE Life Sciences (FRA:1U5) has a Days Payable of 0.00 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on WAVE Life Sciences and its competitors. According to the industry distribution chart, WAVE Life Sciences ranks #999999 out of 702 companies in the Biotechnology industry.
Is WAVE Life Sciences' Days Payable too high?
WAVE Life Sciences' current Days Payable is 0.00. Based on the distribution chart, WAVE Life Sciences ranks #999999 out of 702 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, WAVE Life Sciences has a GF Score™ of 59/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does WAVE Life Sciences' Days Payable compare to CGEM and LXRX?
According to the Biotechnology industry distribution chart, WAVE Life Sciences ranks #999999 out of 702 companies for Days Payable. This places WAVE Life Sciences in the lower half of its industry. The industry median Days Payable is 113.10. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.10, based on 702 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on WAVE Life Sciences and its competitors. For the Biotechnology industry, the median Days Payable is 113.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. WAVE Life Sciences's current Days Payable is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is WAVE Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, WAVE Life Sciences (FRA:1U5) is currently considered Significantly Overvalued. The stock's GF Value™ is €3.80, compared to a current price of €5.40 — trading 42.1% above its estimated fair value. The current Days Payable is 0.00. WAVE Life Sciences' overall GF Score™ is 59/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For WAVE Life Sciences (FRA:1U5), the current Days Payable is 0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is WAVE Life Sciences (FRA:1U5) Overvalued in 2026?
Based on GuruFocus' analysis, WAVE Life Sciences stock appears to be overvalued.
The current stock price of €5.40 is trading 42.1% above its estimated GF Value™ of €3.80.
GuruFocus considers WAVE Life Sciences to be Significantly Overvalued.
Key valuation signals for FRA:1U5:
Days Payable: 0.00
GF Value™: €3.80 vs. price of €5.40 (42.1% above fair value)
No single metric tells the full story. See the FRA:1U5 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.
59GF Score
Get the complete analysis for FRA:1U5
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:1U5 has been successfully added to your 
